{"id":"NCT01723072","sponsor":"Novartis Pharmaceuticals","briefTitle":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-23","primaryCompletion":"2014-05-09","completion":"2014-05-09","firstPosted":"2012-11-07","resultsPosted":"2020-09-09","lastUpdate":"2020-09-09"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria","Angioedema"],"interventions":[{"type":"BIOLOGICAL","name":"Omalizumab","otherNames":["IGE025"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo for Omalizumab"]}],"arms":[{"label":"1 Omalizumab","type":"EXPERIMENTAL"},{"label":"2 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the impact of omalizumab on the quality of life improvement when added to the standard therapy in refractory patients suffering from chronic spontaneous urticaria and angioedema.","primaryOutcome":{"measure":"Mean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)","timeFrame":"Baseline, 4, 12, 20, 28 and 36 weeks","effectByArm":[{"arm":"Omalizumab","deltaMin":-25.5,"sd":21.3},{"arm":"Placebo","deltaMin":-6.4,"sd":15.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":25,"countries":["Germany"]},"refs":{"pmids":["27010957"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":44},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Urticaria","Back pain"]}}